WP
AGIO icon

Woodline Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Woodline Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-74,423
Closed -$2.52M – 1020
2026
Q1 		$2.52M Hold
74,423
– – 0.01% 778
2025
Q4 		$2.03M Buy
74,423
+427
+0.6% +$15K 0.01% 767
2025
Q3 		$2.97M Sell
73,996
-159,072
-68% -$5.98M 0.01% 669
2025
Q2 		$7.75M Buy
233,068
+212,687
+1,044% +$6.45M 0.04% 476
2025
Q1 		$597K Buy
+20,381
New +$676K ﹤0.01% 817
2024
Q3 		– Sell
-113,378
Closed -$4.89M – 592
2024
Q2 		$4.89M Buy
+113,378
New +$4.09M 0.05% 343
2021
Q3 		– Sell
-157,191
Closed -$8.66M – 676
2021
Q2 		$8.66M Sell
157,191
-666,906
-81% -$37.3M 0.16% 149
2021
Q1 		$42.6M Buy
+824,097
New +$40.8M 0.94% 23

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Woodline Partners's AGIO Position: Q2 2026 in Review

Woodline Partners sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 74,423 shares — an estimated $2.52M sold.

Woodline Partners first reported a position in AGIO in Q1 2021 and held it in 8 quarters. The position peaked at $42.6M in Q1 2021. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Woodline Partners reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 74,423 Agios Pharmaceuticals shares in Q2 2026, an estimated $2.52M.
  • Woodline Partners first reported a position in Agios Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Woodline Partners's Agios Pharmaceuticals position peaked at $42.6M in Q1 2021.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.